Skip to main content

Table 3 Characteristics of the patients at the time of inclusion (Day 0) and comparison of the other variables during the study

From: A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis

  Control (n = 30) Antithrombin (n = 30) Pvalue
Age (years) 67 ± 17 73 ± 15 0.174
Gender (male/female) 16/14 19/11 0.601
Sepsis/severe sepsis/septic shock 10/13/7 16/8/6 0.266
APACHE II 20.4 ± 7.1 21.4 ± 9.2 0.638
SIRS 3.0 ± 1.0 3.0 ± 0.9 0.996
SOFA 7.8 ± 3.4 8.5 ± 3.4 0.452
JAAM DIC 5.5 ± 1.3 5.5 ± 1.6 0.858
ISTH DIC 5.2 ± 1.4 5.4 ± 1.1 0.465
Antithrombin (%) 59.1 ± 6.5 61.3 ± 7.5 0.219
Antithrombin (IU/day) - 1752 ± 483 -
Gabexate mesilate (yes/no) 17/13 16/14 1.000
Nafamostat mesilate (yes/no) 3/27 3/27 1.000
Platelet concentrate (yes/no) 6/24 4/26 0.731
Packed red blood cells (yes/no) 11/19 8/22 0.580
Fresh frozen plasma (yes/no) 5/25 1/29 0.19
Lactate (mmol/L) 2.85(1.275-5.525) 1.65(0.975-2.975) 0.051
28-day mortality (%) 13.3 10.0 1.000
Hospital mortality (%) 16.7 20.0 1.000
  1. APACHE, acute physiology and chronic health evaluation; SIRS, systemic inflammatory response syndrome; SOFA, sequential organ failure assessment; JAAM, Japanese Association for Acute Medicine; ISTH, International Society on Thrombosis and Haemostasis.